- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07223125
Badanie leku JNJ-89862175 w leczeniu zaawansowanych guzów litych
Faza 1 badania JNJ-89862175, koniugatu przeciwciała z lekiem przeciwko członkowi rodziny ektopirofosfatazy/fosfodiesterazy 3, w leczeniu zaawansowanych guzów litych
The purpose of this study is to determine safe and effective dose (recommended phase 2 doses [RP2Ds]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.
Przegląd badań
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Study Contact
- Numer telefonu: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Lokalizacje studiów
-
-
-
Lyon, Francja, 69373
- Rekrutacyjny
- Centre Leon Berard
-
Villejuif, Francja, 94805
- Rekrutacyjny
- Gustave Roussy
-
-
-
-
-
Seoul, Korea Południowa, 06351
- Rekrutacyjny
- Samsung Medical Center
-
Seoul, Korea Południowa, 03722
- Rekrutacyjny
- Severance Hospital Yonsei University Health System
-
-
-
-
Florida
-
Orlando, Florida, Stany Zjednoczone, 32803
- Rekrutacyjny
- AdventHealth Orlando
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02114
- Rekrutacyjny
- Massachusetts General Hospital Cancer Center
-
-
Texas
-
Irving, Texas, Stany Zjednoczone, 75039
- Rekrutacyjny
- NEXT Oncology
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Participants must have histologically or cytologically confirmed, metastatic or unresectable solid tumor of lung adenocarcinoma, renal cell carcinoma (RCC): clear cell or papillary carcinoma, endometrioid ovarian cancer and endometrioid uterine carcinoma
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 at screening
- Participants on study drug and for 4 months after the last dose of study drug must not breastfeed or be pregnant, not donate gametes (that is, eggs or sperms) or freeze for future use for the purposes of assisted reproduction and wear an external condom
Exclusion Criteria:
- Active central nervous system (CNS) involvement unless clinically stable
- History of clinically significant cardiovascular disease within 6 months prior to signing informed consent
- History of solid organ or hematologic stem cell transplantation
- Known allergies, hypersensitivity, or intolerance to excipients of JNJ-89862175
- Has prior or concurrent second malignancy (other than the disease under study) in which the natural history or treatment is likely to interfere with safety endpoints or efficacy of the study drug
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: JNJ-89862175
Participants will receive JNJ-89862175 in Part 1 to determine the recommended phase 2 doses (RP2Ds). Dose-escalation and de-escalation will be based on study evaluation team (SET) decision. In Part 2, participants will receive JNJ-89862175 at the RP2Ds determined in Part 1. |
JNJ-89862175 will be administered. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Part 1: Number of Participants with Dose-Limiting Toxicity (DLTs)
Ramy czasowe: Up to 21 days
|
The DLTs are specific adverse events that includes high grade hematologic or non-hematologic toxicities with exceptions and/or toxicities leading to treatment discontinuation. |
Up to 21 days
|
|
Part 1: Number of Participants with Adverse Events (AEs) by Severity
Ramy czasowe: Up to 2 years and 10 months
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product and does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to 2 years and 10 months
|
|
Part 2: Number of Participants with Adverse Events (AEs) by Severity at RP2D
Ramy czasowe: Up to 2 years and 10 months
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product and does not necessarily have a causal relationship with the intervention. Severity will be graded according to the NCI-CTCAE version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to 2 years and 10 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Objective Response Rate (ORR)
Ramy czasowe: Up to 2 years and 10 months
|
ORR is defined as the percentage of participants who have best overall response of complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version (v.) 1.1. |
Up to 2 years and 10 months
|
|
Progression Free Survival (PFS)
Ramy czasowe: Up to 2 years and 10 months
|
PFS is defined as the time from the first dose of JNJ-89862175 to either disease progression according to RECIST v. 1.1, or death due to any cause, whichever comes first. |
Up to 2 years and 10 months
|
|
Duration of Response (DOR)
Ramy czasowe: Up to 2 years and 10 months
|
DOR is defined as the time from the date of initial documentation of a response to the date of first documented evidence of disease progression according to RECIST v. 1.1, or death due to any cause, whichever occurs first. |
Up to 2 years and 10 months
|
|
Maximum Plasma Concentration (Cmax) for JNJ-89862175 (Total and Conjugated Antibody, Free Payload and Major Metabolite)
Ramy czasowe: Up to 2 years and 10 months
|
Serum samples will be analyzed to determine Cmax of JNJ-89862175 with total and conjugated antibody, free payload and major metabolite. |
Up to 2 years and 10 months
|
|
Observed Plasma Concentration Immediately Before Next Dose Administration (Ctrough) of JNJ-89862175 (Total and Conjugated Antibody, Free Payload and Major Metabolite)
Ramy czasowe: Up to 2 years and 10 months
|
Ctrough of JNJ-89862175 with total and conjugated antibody, free payload and major metabolite will be reported. |
Up to 2 years and 10 months
|
|
Time to Reach Cmax (Tmax) for JNJ-89862175 (Total and Conjugated Antibody, Free Payload and Major Metabolite)
Ramy czasowe: Up to 2 years and 10 months
|
Tmax defined as the the time to reach maximum observed plasma concentration of JNJ-89862175 with total and conjugated antibody, free payload and major metabolite will be reported. |
Up to 2 years and 10 months
|
|
Area Under the Plasma Concentration - Time (AUC [0-t]) Curve for JNJ-89862175 (Total and Conjugated Antibody, Free Payload and Major Metabolite)
Ramy czasowe: Up to 2 years and 10 months
|
AUC (0-t) defined as area under the plasma concentration-time curve during a dosing interval of JNJ-89862175 with total and conjugated antibody, free payload and major metabolite will be reported. |
Up to 2 years and 10 months
|
|
Accumulation Ratio of JNJ-89862175 (Total and Conjugated Antibody, Free Payload and Major Metabolite)
Ramy czasowe: Up to 2 years and 10 months
|
Accumulation ratio of JNJ-89862175 with total and conjugated antibody, free payload and major metabolite will be reported. |
Up to 2 years and 10 months
|
|
Number of Participants With Anti JNJ-89862175 Antibodies
Ramy czasowe: Up to 2 years and 10 months
|
Serum samples will be analyzed for the detection of anti-JNJ-89862175 antibodies using a validated assay method. |
Up to 2 years and 10 months
|
Współpracownicy i badacze
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Inne numery identyfikacyjne badania
- 89862175LUC1001
- 89862175LUC1001 (Inny identyfikator: Janssen Research & Development, LLC)
- 2025-521407-52-00 (Identyfikator rejestru: EUCT number)
- 2025 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .